GREEN CROSS

Search
Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
close
Total Menu KOR
close

About usAt a Glance

Key Business &
Therapeutic Area

  • Plasma
    Derivatives
  • Vaccines
  • Consumer Healthcare
  • Cell Therapy
  • Rare Disease
  • Oncology
  • Immunology
  • decoration
  • decoration
  • decoration
  • decoration
  • decoration
  • decoration
  • decoration
  • decoration

Status in
S.Korea

Today, Green Cross is

bulidings

A leading BIOPHARMACEUTICAL company

  • 2nd
    Generating 2nd largest
    annual revenue among
    pharma companies
  • No.1
    • 80%
      Plasma
      Market Share
    • 50%
      Flu vaccine
      Market Share

Status
Overseas

Today, Green Cross is

50 Countries
Exporting PLASMA DERIVATIVES and VACCINES
Top
VACCINE PRODUCER of Pan America Health Organization(PAHO)
Plasma Derivatives Business in 2020
  • Plasma Sourcing30 Global plasma
    collection centers
  • World’s 5th largest manufacturing capacitytotal 2.7 Mℓ from 3 plants
    (In S.Korea, Canada, China)
  • Broad PortfolioProduct Upgrade +
    Innovative Products
  • Commercial Infrastructurein global plasma market

R&D StoryBased on IMMUNOLOGY

  • Plasma Derivatives
  • 1971Albumin
  • 1983Hepavax
  • 1990Hantavax
  • Vaccines
  • 2009GC FLU
  • 2010GreenGene F
  • 2012Hunterase
  • 2014Neulapeg
  • Product
    Upgrade
    Maintain commitment to
    extracting maximum value from
    existing products
  • Innovative
    Products
    Concentrate on developing innovative
    products that align with our technical
    and commercial capabilities
based on immunology